Financial Ratios

JUBILANT PHARMOVA LTD.

NSE : JUBLPHARMABSE : 530019ISIN CODE : INE700A01033Industry : Pharmaceuticals & DrugsHouse : Jubilant Bhartia
BSE665.65-36 (-5.13 %)
PREV CLOSE ( ) 701.65
OPEN PRICE ( ) 699.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 67295
TODAY'S LOW / HIGH ( )658.90 699.65
52 WK LOW / HIGH ( )299.3 724
NSE665.00-35.7 (-5.09 %)
PREV CLOSE( ) 700.70
OPEN PRICE ( ) 700.60
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 665.00 (319)
VOLUME 1015524
TODAY'S LOW / HIGH( ) 655.00 700.60
52 WK LOW / HIGH ( )299.05 724.4
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)3.135.0513.4720.169.27
   CEPS(Rs)5.857.3719.7426.9014.70
   DPS(Rs)5.005.005.005.004.50
   Book NAV/Share(Rs)151.35153.1080.52163.69146.93
   Tax Rate(%)37.134.9921.49-7.4619.52
Margin Ratios
   Core EBITDA Margin(%)0.400.8915.7611.819.33
   EBIT Margin(%)12.0813.1913.8413.869.08
   Pre Tax Margin(%)9.7911.6710.089.525.33
   PAT Margin (%)6.1611.097.9210.234.29
   Cash Profit Margin (%)11.5016.1811.6113.656.81
Performance Ratios
   ROA(%)1.703.425.896.243.11
   ROE(%)2.064.3311.0312.986.43
   ROCE(%)3.674.3611.8210.108.10
   Asset Turnover(x)0.280.310.740.610.72
   Sales/Fixed Asset(x)0.891.432.221.531.96
   Working Capital/Sales(x)3.722.65-50.269.05-207.57
Efficiency Ratios
   Fixed Capital/Sales(x)1.130.700.450.660.51
   Receivable days71.9165.740.0052.6651.70
   Inventory Days143.45162.540.0066.7457.19
   Payable days142.1195.8179.84131.60119.59
Valuation Parameters
   PER(x)89.1076.7450.5312.3471.66
   PCE(x)47.7252.6134.479.2545.19
   Price/Book(x)1.842.538.451.524.52
   Yield(%)1.791.290.732.010.68
   EV/Net Sales(x)5.858.724.171.813.56
   EV/Core EBITDA(x)33.5647.7223.7710.4230.70
   EV/EBIT(x)48.3866.1230.1113.0339.20
   EV/CE(x)1.582.216.121.042.52
   M Cap / Sales5.498.514.001.263.08
Growth Ratio
   Net Sales Growth(%)11.63-73.22-13.71-8.694.00
   Core EBITDA Growth(%)6.41-72.08-12.7236.42-31.87
   EBIT Growth(%)2.26-74.48-13.8139.26-37.88
   PAT Growth(%)-38.03-62.47-33.21117.53-43.96
   EPS Growth(%)-38.03-62.47-33.21117.53-43.96
Financial Stability Ratios
   Total Debt/Equity(x)0.130.070.380.750.73
   Current Ratio(x)1.602.080.551.250.99
   Quick Ratio(x)0.730.800.550.770.61
   Interest Cover(x)5.288.713.683.192.42
   Total Debt/Mcap(x)0.070.030.050.500.16

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.